Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites

Abstract

Conceptualizing AD as an autoimmune disease, identifying endogenous regulators of this autoimmunity, and designing small molecule drug-like analogues of these endogenous regulators represents a novel therapeutic approach for AD.